RU2016139022A - МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ - Google Patents
МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ Download PDFInfo
- Publication number
- RU2016139022A RU2016139022A RU2016139022A RU2016139022A RU2016139022A RU 2016139022 A RU2016139022 A RU 2016139022A RU 2016139022 A RU2016139022 A RU 2016139022A RU 2016139022 A RU2016139022 A RU 2016139022A RU 2016139022 A RU2016139022 A RU 2016139022A
- Authority
- RU
- Russia
- Prior art keywords
- chimeric protein
- residue
- protein according
- multimeric chimeric
- multimeric
- Prior art date
Links
- 108091006056 multimeric chimeric proteins Proteins 0.000 claims 71
- 230000035772 mutation Effects 0.000 claims 21
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 10
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 6
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 5
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 4
- 230000013595 glycosylation Effects 0.000 claims 4
- 238000006206 glycosylation reaction Methods 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl n-(3-chlorophenyl)carbamate Chemical group ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000010118 platelet activation Effects 0.000 claims 2
- 108010004034 stable plasma protein solution Proteins 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403915A GB201403915D0 (en) | 2014-03-05 | 2014-03-05 | Proteins |
| GB1403914.3 | 2014-03-05 | ||
| GB201403914A GB201403914D0 (en) | 2014-03-05 | 2014-03-05 | Proteins |
| GB1403915.0 | 2014-03-05 | ||
| GBGB1405955.4A GB201405955D0 (en) | 2014-04-02 | 2014-04-02 | Proteins |
| GB1405955.4 | 2014-04-02 | ||
| GB1412648.6 | 2014-07-16 | ||
| GB201412648A GB201412648D0 (en) | 2014-07-16 | 2014-07-16 | Proteins |
| PCT/EP2015/054688 WO2015132365A1 (en) | 2014-03-05 | 2015-03-05 | Multimeric fc proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016139022A true RU2016139022A (ru) | 2018-04-25 |
Family
ID=52697365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016139022A RU2016139022A (ru) | 2014-03-05 | 2015-03-05 | МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170081406A1 (OSRAM) |
| EP (1) | EP3114137A1 (OSRAM) |
| JP (1) | JP6851199B2 (OSRAM) |
| KR (1) | KR20160127821A (OSRAM) |
| CN (1) | CN106132994A (OSRAM) |
| AU (1) | AU2015226101B2 (OSRAM) |
| BR (1) | BR112016020377A2 (OSRAM) |
| CA (1) | CA2939201A1 (OSRAM) |
| IL (1) | IL247246A0 (OSRAM) |
| MX (1) | MX2016010953A (OSRAM) |
| RU (1) | RU2016139022A (OSRAM) |
| SG (1) | SG11201606596PA (OSRAM) |
| WO (1) | WO2015132365A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016020368A2 (pt) | 2014-03-05 | 2018-01-23 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| IL286367B2 (en) | 2014-05-02 | 2023-03-01 | Momenta Pharmaceuticals Inc | Compositions and methods relating to engineered fc constructs |
| GB201511787D0 (en) * | 2015-07-06 | 2015-08-19 | Ucb Biopharma Sprl | Proteins |
| GB201513033D0 (en) * | 2015-07-23 | 2015-09-09 | Ucb Biopharma Sprl | Proteins |
| MX394116B (es) | 2015-07-24 | 2025-03-19 | Gliknik Inc | Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada. |
| SG10201911561SA (en) * | 2016-01-27 | 2020-02-27 | CSL Behring Lengnau AG | Recombinant igg fc multimers |
| US12391759B2 (en) | 2016-03-02 | 2025-08-19 | Momenta Pharmaceuticals, Inc. | Methods related to engineered Fc constructs |
| SG11201810465RA (en) | 2016-05-23 | 2018-12-28 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| AU2017279538A1 (en) | 2016-06-07 | 2019-01-03 | Gliknik Inc. | Cysteine-optimized stradomers |
| EP3487534A4 (en) | 2016-07-22 | 2020-03-25 | Gliknik Inc. | FUSION PROTEINS FROM HUMAN PROTEIN FRAGMENTS USED TO CREATE ORDERED MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH IMPROVED FC RECEPTOR BINDING |
| CN110022898B (zh) | 2016-12-09 | 2023-07-04 | 格利克尼克股份有限公司 | 用多价Fc化合物治疗炎性疾病的方法 |
| CN117886928A (zh) | 2017-01-06 | 2024-04-16 | 动量制药公司 | 与经工程改造的Fc构建体相关的组合物和方法 |
| AU2018244574A1 (en) * | 2017-03-28 | 2019-10-31 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
| CA3085385A1 (en) * | 2017-12-14 | 2019-06-20 | CSL Behring Lengnau AG | Recombinant igg fc multimers for the treatment of neuromyelitis optica |
| CN113271972B (zh) | 2018-11-14 | 2025-06-17 | Jn生物科学有限责任公司 | 用于替代IVIG的多聚体杂交Fc蛋白 |
| GB201903767D0 (en) * | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| JP7734652B2 (ja) | 2019-09-13 | 2025-09-05 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体 |
| CN114786721B (zh) * | 2019-12-06 | 2025-10-17 | 康诺贝林伦瑙有限公司 | Fc多聚体的稳定组合物 |
| CN115724985A (zh) * | 2021-08-27 | 2023-03-03 | 三生国健药业（上海）股份有限公司 | 一种cdc平台抗体 |
| CN120060370A (zh) * | 2023-11-29 | 2025-05-30 | 上海科锐克医药科技有限公司 | 用于递送人vegf受体融合蛋白的基因递送载体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2250279T1 (sl) * | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
| JP5604311B2 (ja) * | 2008-03-13 | 2014-10-08 | バイオテスト・アクチエンゲゼルシヤフト | 疾患治療剤 |
| JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| IN2015DN01361A (OSRAM) * | 2012-08-02 | 2015-07-03 | Jn Biosciences Llc |
-
2015
- 2015-03-05 MX MX2016010953A patent/MX2016010953A/es unknown
- 2015-03-05 CN CN201580011852.3A patent/CN106132994A/zh active Pending
- 2015-03-05 JP JP2016555472A patent/JP6851199B2/ja not_active Expired - Fee Related
- 2015-03-05 CA CA2939201A patent/CA2939201A1/en not_active Abandoned
- 2015-03-05 WO PCT/EP2015/054688 patent/WO2015132365A1/en not_active Ceased
- 2015-03-05 BR BR112016020377A patent/BR112016020377A2/pt not_active Application Discontinuation
- 2015-03-05 EP EP15711066.9A patent/EP3114137A1/en not_active Withdrawn
- 2015-03-05 SG SG11201606596PA patent/SG11201606596PA/en unknown
- 2015-03-05 RU RU2016139022A patent/RU2016139022A/ru not_active Application Discontinuation
- 2015-03-05 US US15/123,066 patent/US20170081406A1/en not_active Abandoned
- 2015-03-05 AU AU2015226101A patent/AU2015226101B2/en not_active Ceased
- 2015-03-05 KR KR1020167027644A patent/KR20160127821A/ko not_active Withdrawn
-
2016
- 2016-08-11 IL IL247246A patent/IL247246A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106132994A (zh) | 2016-11-16 |
| CA2939201A1 (en) | 2015-09-11 |
| JP2017509335A (ja) | 2017-04-06 |
| IL247246A0 (en) | 2016-09-29 |
| BR112016020377A2 (pt) | 2018-01-23 |
| AU2015226101A1 (en) | 2016-08-25 |
| MX2016010953A (es) | 2016-11-29 |
| AU2015226101B2 (en) | 2019-08-22 |
| JP6851199B2 (ja) | 2021-03-31 |
| SG11201606596PA (en) | 2016-09-29 |
| WO2015132365A1 (en) | 2015-09-11 |
| EP3114137A1 (en) | 2017-01-11 |
| KR20160127821A (ko) | 2016-11-04 |
| US20170081406A1 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016139022A (ru) | МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ | |
| RU2016139006A (ru) | Мультимерные fc-белки | |
| JP7344858B2 (ja) | Ｆｃ含有ポリペプチドの安定化 | |
| AU2022206732B2 (en) | Antibodies binding to CD3 | |
| AU2021277578B2 (en) | Modified immunoglobulin FC regions | |
| JP6703560B2 (ja) | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃ ｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 | |
| CN103249742B (zh) | 抗人肿瘤坏死因子1型受体抗体 | |
| JP2017512063A5 (OSRAM) | ||
| RU2015152084A (ru) | Гетеромультимеры с уменьшенной или подавленной эффекторной функцией | |
| JP2019519527A (ja) | 操作されたＦｃコンストラクトに関する組成物及び方法 | |
| JP2021500348A (ja) | 単一特異性抗体から多重特異性抗体を生成させるための方法 | |
| JP2017523814A5 (OSRAM) | ||
| JP2017509335A5 (OSRAM) | ||
| CA2993835A1 (en) | Constructs having a sirp-alpha domain or variant thereof | |
| AU2017308590A1 (en) | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions | |
| JP2017506075A5 (OSRAM) | ||
| WO2013004841A1 (en) | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains | |
| JP2015530983A5 (OSRAM) | ||
| IL270897B1 (en) | Immunoglobulin regions that allow heterodimerization | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| JP2023552829A (ja) | 免疫細胞機能を調節するための変異インターロイキン－１０ポリペプチドの抗原結合分子との融合物 | |
| WO2023072217A1 (en) | Fusion proteins targeting cd3 and cd47 | |
| CN113164590A (zh) | 与靶向CCR4的工程化Fc-抗原结合结构域构建体有关的组合物和方法 | |
| CN115151567A (zh) | 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化 | |
| JP2025026957A (ja) | ＩＬ－１β受容体シグナル伝達に干渉する剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180306 |